You are here

Article Text

Article menu

This article has corrections. Please see:

Download PDFPDF

Article
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
Free
  1. S P L Travis1,
  2. E F Stange2,
  3. M Lémann3,
  4. T Öresland4,
  5. Y Chowers5,
  6. A Forbes6,
  7. G D’Haens7,
  8. G Kitis8,
  9. A Cortot9,
  10. C Prantera10,
  11. P Marteau11,
  12. J-F Colombel12,
  13. P Gionchetti13,
  14. Y Bouhnik14,
  15. E Tiret15,
  16. J Kroesen16,
  17. M Starlinger17,
  18. N J Mortensen18,
  19. for the European Crohn’s and Colitis Organisation (ECCO)
  1. 1John Radcliffe Hospital, Oxford, UK
  2. 2Chefarzt, Abteilung für Innere Medizin 1 Schwerpunkte Gastroenterologie, Hepatologie und Endokrinologie, Robert Bosch Krankenhaus, Stuttgart, Germany
  3. 3Service de Gastroentérologie, Hôpital Saint-Louis, Paris, France
  4. 4Colorectal Unit, Department of Surgery, Sahlgrenska Universiteitssjukhuset/Östra, Gothenburg, Sweden
  5. 5Chaim Sheba Medical Center, Tel Hashomer, Israel 52621
  6. 6University College Hospital, London, UK
  7. 7Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
  8. 8Imelda GI Clinical Research Centre, Imelda Hospital, Bonheiden, Belgium
  9. 9Department of Gastroenterology, University Hospital, Lille, France
  10. 10Azienda Ospedaliera S. Camillo-Forlanini, Unita Operativa di Gastroenterologia, Rome, Italy
  11. 11Hospital Européen Department of Gastroenterology, Paris, France
  12. 12Hospital Huriez, Department of HepatoGastroenterology, CH et U, Lille, France
  13. 13Universita di Bologna, Bologna, Italy
  14. 14Hospital Lariboisière, Department of Gastroenterology, Paris, France
  15. 15Inserm, Paris, France, and Universite Pierre et Marie Curie, Paris, France
  16. 16Chirurgische Klinik I (Allgemein-, Gefäβ- und Thoraxchirurgie), Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Berlin, Germany
  17. 17Institute of Pathology, University of Graz, Austria
  18. 18Department of Colorectal Surgery, John Radcliffe, Oxford, UK
  1. Correspondence to:
    Dr S P L Travis
    John Radcliffe Hospital, Oxford OX3 9DU, UK; simon.travis{at}orh.nhs.uk; Professor E F Stange, Department of Internal Medicine 1, Robert Bosch Krankenhaus, PO Box 501120, Auerbachstr 110, 70341 Stuttgart, Germany; Eduard.Stange{at}rbk.de

Abstract

This second section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns treatment of active disease, maintenance of medically induced remission, and surgery. The first section on definitions and diagnosis includes the aims and methods of the consensus, as well as sections on diagnosis, pathology, and classification of Crohn’s disease. The third section on special situations in Crohn’s disease includes postoperative recurrence, fistulating disease, paediatrics, pregnancy, psychosomatics, extraintestinal manifestations, and alternative therapy for Crohn’s disease.

  • 5-ASA, mesalazine
  • AZA, azathioprine
  • CD, Crohn’s disease
  • CDAI, Crohn’s disease activity index
  • CRP, C reactive protein
  • CsA, cyclosporin
  • ECCO, European Crohn’s and Colitis Organisation
  • ESR, erythrocyte sedimentation rate
  • IBD, inflammatory bowel disease
  • IFX, infliximab
  • MTX, methotrexate
  • 6-MP, 6-mercaptopurine
  • NNH, number needed to harm
  • NNT, number needed to treat
  • UC, ulcerative colitis
  • Crohn’s disease
  • treatment
  • mesalazine
  • corticosteroids
  • azathioprine
  • infliximab
  • surgery

https://doi.org/10.1136/gut.2005.081950b

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: the authors have variously received unrestricted educational grants, consultancy fees and/or hospitality from all pharmaceutical companies in the field of inflammatory bowel disease, but no author was paid for this work nor did any company contribute to the consensus statements or text.

    Linked Articles

    • Correction
      CORRECTION
      BMJ Publishing Group Ltd and British Society of Gastroenterology
      Gut 2006; 55 592-592 Published Online First: 10 Mar 2006. doi: 10.1136/gut.2005.08195corr1
    • Digest
      Digest
      Robin Spiller Alastair Watson
      Gut 2006; 55 437-437 Published Online First: 10 Mar 2006.